Novo Nordisk $NVO explores the hair loss market to diversify beyond weight loss drugs and target $23B in pipeline sales by 2035! KEY HIGHLIGHTS: • Aims to launch 5+ multi-blockbuster treatments by 2030, building toward $23B in pipeline sales by 2035 • Maintains elite fundamental execution with a 35.35% net margin and a 59.82% Return on Equity (ROE) • Strategic comments boosted peer hair loss developers like Absci and Veradermics THE RATING: Strong 35.35% net margins and pipeline expansion goals balance against post-2030 GLP-1 patent cliff concerns, keeping the Seeking Alpha Quant score for $NVO at a HOLD. Can Novo Nordisk's expansion into hair loss offset future patent cliff risks, or are you holding off on $NVO until pipeline results roll in? Drop your take below! ▻